658 related articles for article (PubMed ID: 2915665)
1. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.
Selwyn PA; Hartel D; Lewis VA; Schoenbaum EE; Vermund SH; Klein RS; Walker AT; Friedland GH
N Engl J Med; 1989 Mar; 320(9):545-50. PubMed ID: 2915665
[TBL] [Abstract][Full Text] [Related]
2. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy.
Selwyn PA; Sckell BM; Alcabes P; Friedland GH; Klein RS; Schoenbaum EE
JAMA; 1992 Jul 22-29; 268(4):504-9. PubMed ID: 1619742
[TBL] [Abstract][Full Text] [Related]
3. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
[TBL] [Abstract][Full Text] [Related]
4. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection.
Caiaffa WT; Graham NM; Galai N; Rizzo RT; Nelson KE; Vlahov D
Arch Intern Med; 1995 Oct; 155(19):2111-7. PubMed ID: 7575072
[TBL] [Abstract][Full Text] [Related]
5. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
Jansà JM; Serrano J; Caylà JA; Vidal R; Ocaña I; Español T
Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
[TBL] [Abstract][Full Text] [Related]
6. Tuberculin skin testing in intravenous drug users: differences between HIV-seropositive and HIV-seronegative subjects.
Portu JJ; Aldamiz-Etxebarria M; Agud JM; Arévalo JM; Almaraz MJ; Ayensa C
Addict Biol; 2002 Apr; 7(2):235-41. PubMed ID: 12006219
[TBL] [Abstract][Full Text] [Related]
7. [Risk of tuberculosis in parenteral drug addicts with human immunodeficiency virus seropositivity. A cohort study in detoxication communities].
Solera J; López E; Serna E; Vergara L; Martínez-Alfaro E; Sáez L
Med Clin (Barc); 1993 May; 100(19):725-9. PubMed ID: 8315960
[TBL] [Abstract][Full Text] [Related]
8. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
[TBL] [Abstract][Full Text] [Related]
9. [Risk of tuberculosis in a cohort of HIV positive IVDA patients in relation to the degree of immunodeficiency and tuberculosis skin test].
Cabarcos Ortíz de Barrón A; Barrio Gómez E; Lado Lado FL; Lorenzo Zúñiga V
An Med Interna; 2000 Sep; 17(9):465-70. PubMed ID: 11100532
[TBL] [Abstract][Full Text] [Related]
10. The incidence of tuberculosis in drug users with small tuberculin reaction sizes.
Klein RS; Gourevitch MN; Teeter R; Schoenbaum EE
Int J Tuberc Lung Dis; 2001 Aug; 5(8):707-11. PubMed ID: 11495260
[TBL] [Abstract][Full Text] [Related]
11. Sexual practices and condom usage in a cohort of homosexual men in relation to human immunodeficiency virus status.
Tindall B; Swanson C; Donovan B; Cooper DA
Med J Aust; 1989 Sep; 151(6):318-22. PubMed ID: 2593942
[TBL] [Abstract][Full Text] [Related]
12. [Prevalence of human immunodeficiency virus type 1 and Mycobacterium tuberculosis infections in a prison population in the years 1989 to 1995].
Pérez-Agudo F; Alonso Moreno FJ; Urbina Torija J
Med Clin (Barc); 1998 Feb; 110(5):167-70. PubMed ID: 9547719
[TBL] [Abstract][Full Text] [Related]
13. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection.
Selwyn PA; Alcabes P; Hartel D; Buono D; Schoenbaum EE; Klein RS; Davenny K; Friedland GH
N Engl J Med; 1992 Dec; 327(24):1697-703. PubMed ID: 1359411
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users.
Graham NM; Nelson KE; Solomon L; Bonds M; Rizzo RT; Scavotto J; Astemborski J; Vlahov D
JAMA; 1992 Jan; 267(3):369-73. PubMed ID: 1727959
[TBL] [Abstract][Full Text] [Related]
15. Risk of reactivation of tuberculosis in the course of human immunodeficiency virus infection.
Di Perri G; Micciolo R; Vento S; Cruciani M; Marocco S; Carlotto A; Adami T; Mazzi R; Cazzadori A; Concia E
Eur J Med; 1993 May; 2(5):264-8. PubMed ID: 7902760
[TBL] [Abstract][Full Text] [Related]
16. [Tuberculosis in HIV-positive and HIV-negative drug users in Amsterdam].
Keizer ST; Langendam MW; van Deutekom H; Coutinho RA; van Ameijden FJ
Ned Tijdschr Geneeskd; 1998 Jan; 142(4):184-9. PubMed ID: 9557024
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
18. Self-assessment of tuberculin skin test reactions by drug users with or at risk for human immunodeficiency virus infection.
Gourevitch MN; Teeter R; Schoenbaum EE; Klein RS
Int J Tuberc Lung Dis; 1999 Apr; 3(4):321-5. PubMed ID: 10206502
[TBL] [Abstract][Full Text] [Related]
19. Survival in a cohort of human immunodeficiency virus-infected tuberculosis patients in New York City. Implications for the expansion of the AIDS case definition.
Stoneburner R; Laroche E; Prevots R; Singh T; Blum S; Terry P; Reatrice S; Adler J
Arch Intern Med; 1992 Oct; 152(10):2033-7. PubMed ID: 1358042
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of and risk factors for HIV-1 infection in injection drug users in Montreal and Toronto: a collaborative study.
Lamothe F; Bruneau J; Coates R; Rankin JG; Soto J; Arshinoff R; Brabant M; Vincelette J; Fauvel M
CMAJ; 1993 Oct; 149(7):945-51. PubMed ID: 8402423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
